vs
Apellis Pharmaceuticals, Inc.（APLS）与JBG SMITH Properties（JBGS）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是JBG SMITH Properties的1.6倍（$199.9M vs $127.6M），Apellis Pharmaceuticals, Inc.净利率更高（-29.5% vs -35.7%，领先6.2%），JBG SMITH Properties同比增速更快（-2.5% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -6.3%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
JBG SMITH Properties是一家总部位于马里兰州贝塞斯达的上市房地产投资信托公司，专注于持有并运营房地产资产，是美国商业地产领域的专业运营机构，面向市场提供多元化的不动产投资与管理服务。
APLS vs JBGS — 直观对比
营收规模更大
APLS
是对方的1.6倍
$127.6M
营收增速更快
JBGS
高出3.5%
-5.9%
净利率更高
APLS
高出6.2%
-35.7%
两年增速更快
APLS
近两年复合增速
-6.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $127.6M |
| 净利润 | $-59.0M | $-45.5M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | -47.5% |
| 净利率 | -29.5% | -35.7% |
| 营收同比 | -5.9% | -2.5% |
| 净利润同比 | -62.2% | 24.0% |
| 每股收益（稀释后） | $-0.40 | $-0.76 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSJBGS
| Q4 25 | $199.9M | $127.6M | ||
| Q3 25 | $458.6M | $123.9M | ||
| Q2 25 | $178.5M | $126.5M | ||
| Q1 25 | $166.8M | $120.7M | ||
| Q4 24 | $212.5M | $130.8M | ||
| Q3 24 | $196.8M | $136.0M | ||
| Q2 24 | $199.7M | $135.3M | ||
| Q1 24 | $172.3M | $145.2M |
净利润APLSJBGS
| Q4 25 | $-59.0M | $-45.5M | ||
| Q3 25 | $215.7M | $-28.6M | ||
| Q2 25 | $-42.2M | $-19.2M | ||
| Q1 25 | $-92.2M | $-45.7M | ||
| Q4 24 | $-36.4M | $-59.9M | ||
| Q3 24 | $-57.4M | $-27.0M | ||
| Q2 24 | $-37.7M | $-24.4M | ||
| Q1 24 | $-66.4M | $-32.3M |
营业利润率APLSJBGS
| Q4 25 | -25.6% | -47.5% | ||
| Q3 25 | 48.7% | -27.5% | ||
| Q2 25 | -18.6% | -18.4% | ||
| Q1 25 | -50.0% | -44.7% | ||
| Q4 24 | -12.3% | -53.6% | ||
| Q3 24 | -24.0% | -22.4% | ||
| Q2 24 | -14.7% | -24.3% | ||
| Q1 24 | -36.0% | -30.1% |
净利率APLSJBGS
| Q4 25 | -29.5% | -35.7% | ||
| Q3 25 | 47.0% | -23.1% | ||
| Q2 25 | -23.6% | -15.2% | ||
| Q1 25 | -55.3% | -37.9% | ||
| Q4 24 | -17.1% | -45.8% | ||
| Q3 24 | -29.2% | -19.8% | ||
| Q2 24 | -18.9% | -18.0% | ||
| Q1 24 | -38.5% | -22.2% |
每股收益（稀释后）APLSJBGS
| Q4 25 | $-0.40 | $-0.76 | ||
| Q3 25 | $1.67 | $-0.48 | ||
| Q2 25 | $-0.33 | $-0.29 | ||
| Q1 25 | $-0.74 | $-0.56 | ||
| Q4 24 | $-0.30 | $-0.70 | ||
| Q3 24 | $-0.46 | $-0.32 | ||
| Q2 24 | $-0.30 | $-0.27 | ||
| Q1 24 | $-0.54 | $-0.36 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $75.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $1.2B |
| 总资产 | $1.1B | $4.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSJBGS
| Q4 25 | $466.2M | $75.3M | ||
| Q3 25 | $479.2M | $64.4M | ||
| Q2 25 | $370.0M | $61.4M | ||
| Q1 25 | $358.4M | $81.3M | ||
| Q4 24 | $411.3M | $145.8M | ||
| Q3 24 | $396.9M | $137.0M | ||
| Q2 24 | $360.1M | $163.5M | ||
| Q1 24 | $325.9M | $220.5M |
总债务APLSJBGS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSJBGS
| Q4 25 | $370.1M | $1.2B | ||
| Q3 25 | $401.2M | $1.2B | ||
| Q2 25 | $156.3M | $1.3B | ||
| Q1 25 | $164.2M | $1.6B | ||
| Q4 24 | $228.5M | $1.8B | ||
| Q3 24 | $237.1M | $1.9B | ||
| Q2 24 | $264.3M | $2.0B | ||
| Q1 24 | $266.7M | $2.1B |
总资产APLSJBGS
| Q4 25 | $1.1B | $4.4B | ||
| Q3 25 | $1.1B | $4.4B | ||
| Q2 25 | $821.4M | $4.5B | ||
| Q1 25 | $807.3M | $4.7B | ||
| Q4 24 | $885.1M | $5.0B | ||
| Q3 24 | $901.9M | $5.2B | ||
| Q2 24 | $904.5M | $5.3B | ||
| Q1 24 | $831.9M | $5.4B |
负债/权益比APLSJBGS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $73.3M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSJBGS
| Q4 25 | $-14.2M | $73.3M | ||
| Q3 25 | $108.5M | $8.9M | ||
| Q2 25 | $4.4M | $18.8M | ||
| Q1 25 | $-53.4M | $12.9M | ||
| Q4 24 | $19.4M | $129.4M | ||
| Q3 24 | $34.1M | $26.4M | ||
| Q2 24 | $-8.3M | $23.8M | ||
| Q1 24 | $-133.0M | $37.0M |
自由现金流APLSJBGS
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — | ||
| Q1 24 | $-133.3M | — |
自由现金流率APLSJBGS
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — | ||
| Q1 24 | -77.3% | — |
资本支出强度APLSJBGS
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
现金转化率APLSJBGS
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
JBGS
暂无分部数据
